Assessment of Clinical Disease Activity and Disability Improvement by Number-Needed-To-Treat Analyses in Patients with Relapsing Multiple Sclerosis Treated with Alemtuzumab Or Ocrelizumab

Raed Alroughani, Giancarlo Comi, Regina Berkovich, Guillermo Izquierdo, Daniel Kantor, Christopher LaGanke, Volker Limmroth, Richard AL Macdonell, Basil Sharrack, Heinz Wiendl